Selected References:

  • Bove R. 2016. Women’s Issues in Multiple Sclerosis. Semin Neurol. 36(2):154-62.
  • Cavalla P, et al. 2006. Fertility in patients with multiple sclerosis: current knowledge and future perspectives. Neurol Sci 27(4):231-239.
  • Confavreux C, et al. 1998. Rate of pregnancy-related relapse in multiple sclerosis. N Engl J Med 339:285-291.
  • Coyle PK. 2016. Management of women with multiple sclerosis through pregnancy and after childbirth. Ther Adv Neurol Disord. May;9(3):198-210.
  • Cuello JP, et al. 2017. Multiple sclerosis and pregnancy: a single-centre prospective comparative study. Neurologia. 32(2):92-98.
  • Finkelsztejn A, et al. 2011. What can we really tell women with multiple sclerosis regarding their pregnancy? A systematic review and meta-analysis of the literature. BJOG 118:790-797.
  • Fragoso YD, et al. 2013. The effects of long-termexposure to disease-modifying drugs during pregnancy in multiple sclerosis, Clin Neurol Neurosurg. Feb;115(2): 154-9.
  • Ghezzi A, et al. 2013. Current recommendations for multiple sclerosis treatment in pregnancy and puerperium. Expert Rev Clin Immunol. 2013 Jul;9(7):683-91.
  • Hughes SE, et al. 2014. Predictors and dynamics of postpartum relapses in women with multiple sclerosis. Mult Scler 20(6) 739–746.
  • Jokubaitis VG, et al; MSBase Study Group. 2016. Predictors of long-term disability accrual in relapse-onset multiple sclerosis. Ann Neurol. 80(1):89-100.
  • Lu E, et al. 2014. Birth outcomes of pregnancies fathered by men with multiple sclerosis. Mult Scler Feb;20(9):1260-1264.
  • Neuteboom RF, et al. 2012. Pregnancy in multiple sclerosis: clinical and self-report scales. J Neurol. 259(2):311-7.
  • Paidas PJ, et al. 2012. Pregnancy and multiple sclerosis (MS): A beneficial association. Possible therapeutic application of embryo-specific Pre-implantation Factor (PIF*). Am J Reprod Immunol 68(6):456-64.
  • Pecori C, et al. 2014. Paternal therapy with disease modifying drugs in multiple sclerosis and pregnancy outcomes: a prospective observational multicentric study. BMC Neurol. 14:114.
  • Safarinejad MR. 2008. Evaluation of endocrine profile, hypothalamic-pituitary-testis axis and semen quality in multiple sclerosis. J Neuroendocrinol. 20(12):1368-1375.
  • Salminen HJ, et al. 2010. Glatiramer acetate exposure in pregnancy: preliminary safety and birth outcomes. J Neurol. 257(12): 2020-2023.
  • Tsui A and Lee MA. 2011. Multiple sclerosis and pregnancy. Curr Opin Obstet Gynecol 23(6):435-439.
  • Voskuhl R, Momtazee C. 2017. Pregnancy: Effect on Multiple Sclerosis, Treatment Considerations, and Breastfeeding. Neurotherapeutics. 14(4):974-984.
  • Weber-Schoendorfer C and Schaefer C. 2009. Multiple sclerosis, immunomodulators, and pregnancy outcome: a prospective observational study. Mult Scler 15(9):1037-1042.
  • Ziemssen T, et al. 2001. Risk-benefit assessment of glatiramer acetate in multiple sclerosis. Drug Saf. 24(13):979-990.